Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Seikagaku Corporation

http://www.seikagaku.co.jp/english/

Latest From Seikagaku Corporation

News We’re Watching: Self-Powered Pacemakers, Artificial Hearts, And More

Medtech Insight's News We're Watching highlights medtech industry developments that you may have missed over the last few weeks. Chinese researchers are working on a self-powered pacemaker, Carmat updated its artificial heart progress, a trial validates Smith & Nephew's Regeneten implant in shoulder surgery, experts back intravascular IVUS in peripheral interventions, and Spectral AI launches a new trial of its AI for burn evaluation.

News We're Watching Artificial Intelligence

Lumineux Called For Foul In Teeth Whitening Claim Review For Implying ‘Harm’ From Crest Whitestrips

National Advertising Division recommends Oral Essentials discontinue  claims on packaging that Lumineux strips are "first on the market that are delicious and clinically proven to whiten teeth as well as the leading brand, without the harm associated with bleaches.”

Ad Complaints OTC Drugs

Sanofi’s Tzield Delays Children’s Type 1 Diabetes Progression, But Falls Short On Clinical Impact

Sanofi paid $2.9bn for Tzield and its developer Provention earlier this year, but a mixed readout in its key Phase III study will raise doubts among analysts about its long-term prospects in later-stage patients.

Clinical Trials Commercial

‘Transparency-Rx’: Meet The PBM Execs Breaking Rank And Backing Reforms

New coalition of smaller PBMs champions federal policies requiring ‘100% pass-through’ of rebates, with PBMs then paid by a flat, disclosed fee.

Pricing Debate Leadership
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Seikagaku North America Corporation
UsernamePublicRestriction

Register